Nicotinamide and Pyruvate in Open-Angle Glaucoma: A Randomized Controlled Trial on Neuroprotection-Design and Methodology.

What Was Tested

Researchers studied NAD+ in this randomized controlled trial publication.

The Nicotinamide and Pyruvate in Open-Angle Glaucoma Trial aims to establish whether nicotinamide and pyruvate dietary supplementation provides neuroprotection in eyes with treated open-angle glaucoma (OAG).

Why It Was Studied

Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Who Took Part

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

Open-angle glaucoma patients recruited at Columbia University Irving Medical Center and Stanford University between March 1, 2023, and August 30, 2025.

Standard-of-care intraocular pressure-lowering treatment is continued throughout the study and can be modified at the discretion of the treating physician.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this NAD+ study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received NAD+.

The comparison arm used a placebo, so changes seen with NAD+ could be set against what happens without it.

A prospective, two-site, 21-month, placebo-controlled, double-masked, phase III randomized clinical trial.

What Was Measured

The subject headings attached to it are Glaucoma, Open-Angle, Niacinamide, Intraocular Pressure, Pyruvic Acid, Visual Fields, Neuroprotective Agents and Dietary Supplements.

Author keywords: Neuroprotection, Neurorecovery, Nicotinamide and Pyruvate.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of NAD+.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2026 (Ophthalmology. Glaucoma), a journal based in United States.

More context: the NAD+ compound page, all human trials.